Cancel
Rapt Therapeutics
Rapt Therapeutics Employees
12 people indexed:
-
qlw22j@8ee4.5wz Sign up to see email
-
gg9v2s@0gyh.q67 Sign up to see email
-
David Wustrow, Ph.D.
Senior Vice President, Drug Discovery and Preclinical Development
gnbhbn@k3h5.qxh Sign up to see email03n1js@9u56.k8u Sign up to see email -
99s71@g24e.820 Sign up to see email
-
5s91q@x1x0.l1x Sign up to see email
-
Jennifer Nicholson
Senior Vice President, Regulatory Affairs and Quality Assurance
z01bwud5g@qk26.vz1 Sign up to see email0w015w11g@yyu5.83u Sign up to see email -
Lisa Moore, Ph.D.
Vice President, Business Development and Strategy
58v5e@79v8.565 Sign up to see email332ev@6d3b.x06 Sign up to see email -
y3kgdu1v@j8q4.gfv Sign up to see email
-
06w3fg@68q3.3gx Sign up to see email
-
Paul Kassner, Ph.D.
Senior Vice President, Quantitative and Computational Biology
3iwiy@0zv1.89y Sign up to see emailv97id@442i.bxw Sign up to see email -
u67kkqu@fj80.xb9 Sign up to see email
-
gy81k4nx@3s7n.27e Sign up to see email
Rapt Therapeutics Company Information
Rapt Therapeutics, formerly known as FLX Bio, Inc., is a biopharmaceutical company based in South San Francisco, California, specializing in the development of oral small molecule therapies. The company’s efforts are concentrated on creating treatments that modulate the immune system, targeting key drivers of inflammation and cancer. Rapt Therapeutics utilizes a proprietary drug discovery and development engine to advance its research. Its lead drug candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), both target the C-C motif chemokine receptor 4 (CCR4). Zelnecirnon is currently under clinical evaluation for the potential treatment of eczema and asthma, while tivumecirnon is being tested for its effectiveness against various types of cancer. The company is actively engaged in clinical trials, investigating these candidates for the treatment of atopic dermatitis, asthma, and various cancers. Rapt Therapeutics is publicly traded on the Nasdaq Global Market under the ticker symbol ‘RAPT’.
Report inaccurate information
Report inaccurate information
